Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, C4 Therapeutics's Enterprise Value is $307.60 Mil.
C4 Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-84.87 Mil. Therefore, C4 Therapeutics's EV-to-OCF for today is -3.62.
The historical rank and industry rank for C4 Therapeutics's EV-to-OCF or its related term are showing as below:
CCCC'
s EV-to-OCF Range Over the Past 10 Years
Min: -23.45 Med: -1.98 Max: 0.85
Current: -3.62
During the past 8 years, the highest EV-to-OCF of C4 Therapeutics was 0.85. The lowest was -23.45. And the median was -1.98.
CCCC's EV-to-OCF is ranked worse than 50.11% of 1409
companies
in the Biotechnology industry
Industry Median: -3.63
vs CCCC: -3.62
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
C4 Therapeutics's PE Ratio (TTM) for today is calculated as:
C4 Therapeutics's share price for today is $4.115.
C4 Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
C4 Therapeutics EV-to-OCF Related Terms
C4 Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for C4 Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, C4 Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C4 Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, C4 Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where C4 Therapeutics's EV-to-OCF falls into.
C4 Therapeutics's current Enterprise Value is $307.60 Mil.
C4 Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C4 Therapeutics (CCCC) has a EV-to-OCF of -3.62 as of Aug. 25, 2026. According to the industry distribution chart, C4 Therapeutics ranks #706 out of 1409 companies in the Biotechnology industry, placing it in the top 50.1%.
Is C4 Therapeutics' EV-to-OCF too high?
C4 Therapeutics' current EV-to-OCF is -3.62. Based on the distribution chart, C4 Therapeutics ranks #706 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, C4 Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C4 Therapeutics' EV-to-OCF compare to CMPX and AVIR?
According to the Biotechnology industry distribution chart, C4 Therapeutics ranks #706 out of 1409 companies for EV-to-OCF. This places C4 Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. C4 Therapeutics's current EV-to-OCF is -3.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C4 Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, C4 Therapeutics (CCCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.05, compared to a current price of $4.12 — trading 100.7% above its estimated fair value. The current EV-to-OCF is -3.62. C4 Therapeutics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For C4 Therapeutics (CCCC), the current EV-to-OCF is -3.62 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C4 Therapeutics (CCCC) Overvalued in 2026?
Based on GuruFocus' analysis, C4 Therapeutics stock appears to be overvalued.
The current stock price of $4.12 is trading 100.7% above its estimated GF Value™ of $2.05.
GuruFocus considers C4 Therapeutics to be Significantly Overvalued.
Key valuation signals for CCCC:
EV-to-OCF: -3.62
GF Value™: $2.05 vs. price of $4.12 (100.7% above fair value)
No single metric tells the full story. See the CCCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
49GF Score
Get the complete analysis for CCCC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCCC has been successfully added to your 
